# Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Source: https://onco.cc/trials/nct05171816/  
OnCo record `nct05171816` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Olaparib, Abiraterone acetate in prostate cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) is a phase 3 interventional study registered as NCT05171816 by AstraZeneca, with 110 participants enrolled, started 2021-06-24 and due to reach its primary completion in 2024-01-22. Interventions recorded: olaparib, abiraterone acetate. Conditions listed: Metastatic Castration-resistant Prostate Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT05171816
- Phase: 3
- Setting: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)
- Sponsor: AstraZeneca
- Enrolled: 110
- Outcomes: Radiological Progression Free Survival (rPFS): Olaparib 300 mg bd + Abiraterone 1000 mg qd 14.75 months vs Placebo bd + Abiraterone 1000 mg qd, HR 1.43; Overall Survival (OS): Olaparib 300 mg bd + Abiraterone 1000 mg qd 27.83 months vs Placebo bd + Abiraterone 1000 mg qd, HR 1.14

## Sources

- ClinicalTrials.gov NCT05171816: https://clinicaltrials.gov/study/NCT05171816

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- ideas: [Prescribe a quarter dose of abiraterone with breakfast](https://onco.cc/ideas/idea-cost-low-dose-abiraterone-food/)

---
JSON: https://onco.cc/api/v1/entities/nct05171816.json